PL2417158T3 - Przeciwciała DKK-1 - Google Patents

Przeciwciała DKK-1

Info

Publication number: PL2417158T3
Authority: PL; Poland
Prior art keywords: dkk; antibodies
Prior art date: 2009-04-10

Application number

PL10712681T

Other languages

English (en)

Inventor

Marcio Chedid

Ryan James Darling

Rachelle Jeanette Galvin

Barbara Anne Swanson

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-10

Filing date

2010-04-06

Publication date

2017-12-29

2010-04-06 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2017-12-29 Publication of PL2417158T3 publication Critical patent/PL2417158T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL10712681T 2009-04-10 2010-04-06 Przeciwciała DKK-1 PL2417158T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16841109P	2009-04-10	2009-04-10
PCT/US2010/030039 WO2010117980A1 (en)	2009-04-10	2010-04-06	Dkk-1 antibodies
EP10712681.5A EP2417158B9 (en)	2009-04-10	2010-04-06	Dkk-1 antibodies

Publications (1)

Publication Number	Publication Date
PL2417158T3 true PL2417158T3 (pl)	2017-12-29

Family

ID=42199718

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL15159780T PL2930184T3 (pl)	2009-04-10	2010-04-06	Przeciwciała DKK-1
PL10712681T PL2417158T3 (pl)	2009-04-10	2010-04-06	Przeciwciała DKK-1
PL19156509T PL3514173T3 (pl)	2009-04-10	2010-04-06	Przeciwciała DKK-1

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL15159780T PL2930184T3 (pl)	2009-04-10	2010-04-06	Przeciwciała DKK-1

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL19156509T PL3514173T3 (pl)	2009-04-10	2010-04-06	Przeciwciała DKK-1

Country Status (30)

Country	Link
US (1)	US8148498B2 (pl)
EP (3)	EP2417158B9 (pl)
JP (1)	JP5759977B2 (pl)
KR (3)	KR20110124364A (pl)
CN (1)	CN102388065B (pl)
AR (1)	AR075989A1 (pl)
AU (1)	AU2010234611B2 (pl)
BR (1)	BRPI1014157B1 (pl)
CA (1)	CA2758252C (pl)
CY (3)	CY1119399T1 (pl)
DK (3)	DK2930184T3 (pl)
EA (1)	EA021401B1 (pl)
ES (3)	ES2887176T3 (pl)
HR (3)	HRP20171400T1 (pl)
HU (3)	HUE055376T2 (pl)
IL (1)	IL214845A (pl)
LT (3)	LT2930184T (pl)
ME (2)	ME02798B (pl)
MX (1)	MX2011010707A (pl)
NZ (1)	NZ595011A (pl)
PL (3)	PL2930184T3 (pl)
PT (3)	PT2930184T (pl)
RS (3)	RS58612B1 (pl)
SG (1)	SG175244A1 (pl)
SI (3)	SI2930184T1 (pl)
TR (1)	TR201907261T4 (pl)
TW (1)	TWI546079B (pl)
UA (1)	UA103916C2 (pl)
WO (1)	WO2010117980A1 (pl)
ZA (1)	ZA201107256B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20120475A1 (es)	2009-05-12	2012-05-05	Pfizer	Anticuerpos especificos para dkk-1
CN111961134B (zh)	2012-12-10	2024-04-05	比奥根Ma公司	抗血液树突细胞抗原2抗体及其用途
AU2016263030A1 (en) *	2015-05-18	2017-10-12	Eli Lilly And Company	Anti-Dkk-1-anti-RANKL bispecific antibody compounds
CA2996059A1 (en) *	2015-08-28	2017-03-09	Alector Llc	Anti-siglec-7 antibodies and methods of use thereof
EP3370768B9 (en)	2015-11-03	2022-03-16	Janssen Biotech, Inc.	Antibodies specifically binding pd-1 and their uses
KR102701695B1 (ko)	2016-10-26	2024-08-30	리프 테라퓨틱스 인코포레이티드	항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
MX2020013172A (es)	2018-06-08	2021-03-29	Alector Llc	Anticuerpos anti-siglec-7 y sus metodos de uso.
AU2019301160A1 (en) *	2018-07-11	2021-02-25	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CTLA-4
CN112121147B (zh) *	2019-06-24	2023-07-04	中国人民解放军海军特色医学中心	多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
BR112022004851A2 (pt) *	2019-09-19	2022-08-23	Leap Therapeutics Inc	Uso de inibidores de dkk-1 para tratar câncer
EP4061419A1 (en)	2019-11-22	2022-09-28	Leap Therapeutics, Inc.	Methods of treating cancer using dkk-1-inhibitors
KR102494042B1 (ko)	2020-11-20	2023-02-07	주식회사 하울바이오	인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) *	2020-12-02	2022-04-26	杭州奕安济世生物药业有限公司	抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
IL304927A (en) *	2021-02-05	2023-10-01	Omeros Corp	A biomarker for assessing the risk of developing acute COVID-19 and post-acute COVID-19
WO2023039249A1 (en)	2021-09-10	2023-03-16	Leap Therapeutics, Inc.	Combination therapy
EP4471056A4 (en) *	2022-01-28	2026-02-18	Shanghai Junshi Biosciences Co Ltd	Anti-DKK1 antibodies, pharmaceutical composition and associated uses
KR20250057775A (ko)	2022-07-12	2025-04-29	리프 테라퓨틱스 인코포레이티드	조합 요법
CN116589590B (zh) *	2023-03-21	2024-03-26	浙江大学	一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
AU7137398A (en)	1997-04-16	1998-11-11	Millennium Pharmaceuticals, Inc.	Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
DE19747418C1 (de) *	1997-10-27	1999-07-15	Deutsches Krebsforsch	Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) *	1998-01-15	2008-11-04	Millennium Pharmaceuticals, Inc.	Antibodies that bind human Dickkopf-1 proteins
JP3868740B2 (ja)	1998-03-10	2007-01-17	ジェネンテック・インコーポレーテッド	新規なポリペプチド及びそれをコードする核酸
CA2399776A1 (en)	2000-02-03	2001-08-09	Hyseq, Inc.	Novel nucleic acids and polypeptides
US7736654B2 (en)	2001-04-10	2010-06-15	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL158750A0 (en)	2001-05-17	2004-05-12	Genome Therapeutics Corp	Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) *	2002-05-17	2004-02-26	Allen Kristina M.	Reagents and methods for modulating dkk-mediated interactions
US7371736B2 (en) *	2001-11-07	2008-05-13	The Board Of Trustees Of The University Of Arkansas	Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) *	2001-11-07	2007-12-11	The University Of Arkansas For Medical Sciences	Diagnosis of multiple myeloma on gene expression profiling
JP2005512557A (ja)	2001-11-07	2005-05-12	ザボードオブトラスティーズオブザユニヴァーシティーオブアーカンソー	遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
US7642238B2 (en) *	2002-12-05	2010-01-05	Shaughnessy John D	Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) *	2003-05-21	2005-04-21	Darwin Prockop	Inhibitors of Dkk-1
EP1636388A2 (en)	2003-06-06	2006-03-22	Wyeth	Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
MX2007001221A (es)	2004-08-04	2007-03-23	Amgen Inc	Anticuerpos para proteina dickkopf-1 (dkk-1).
AR060017A1 (es) *	2006-01-13	2008-05-21	Novartis Ag	Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) *	2007-02-08	2015-02-11	默沙东公司	Dkk-1的特异性抗体
CN102421798A (zh) *	2009-05-07	2012-04-18	诺瓦提斯公司	与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法

2010
- 2010-03-29 AR ARP100101019A patent/AR075989A1/es active IP Right Grant
- 2010-04-02 TW TW099110438A patent/TWI546079B/zh active
- 2010-04-06 SI SI201031877T patent/SI2930184T1/sl unknown
- 2010-04-06 US US12/754,637 patent/US8148498B2/en active Active
- 2010-04-06 ME MEP-2017-212A patent/ME02798B/me unknown
- 2010-04-06 SI SI201031526T patent/SI2417158T1/sl unknown
- 2010-04-06 NZ NZ595011A patent/NZ595011A/xx unknown
- 2010-04-06 SI SI201032080T patent/SI3514173T1/sl unknown
- 2010-04-06 HR HRP20171400TT patent/HRP20171400T1/hr unknown
- 2010-04-06 KR KR1020117023571A patent/KR20110124364A/ko not_active Ceased
- 2010-04-06 BR BRPI1014157-0A patent/BRPI1014157B1/pt active IP Right Grant
- 2010-04-06 PL PL15159780T patent/PL2930184T3/pl unknown
- 2010-04-06 JP JP2012504760A patent/JP5759977B2/ja active Active
- 2010-04-06 PT PT15159780T patent/PT2930184T/pt unknown
- 2010-04-06 EA EA201171237A patent/EA021401B1/ru not_active IP Right Cessation
- 2010-04-06 MX MX2011010707A patent/MX2011010707A/es active IP Right Grant
- 2010-04-06 EP EP10712681.5A patent/EP2417158B9/en active Active
- 2010-04-06 LT LTEP15159780.4T patent/LT2930184T/lt unknown
- 2010-04-06 ES ES19156509T patent/ES2887176T3/es active Active
- 2010-04-06 DK DK15159780.4T patent/DK2930184T3/da active
- 2010-04-06 DK DK10712681.5T patent/DK2417158T4/da active
- 2010-04-06 AU AU2010234611A patent/AU2010234611B2/en active Active
- 2010-04-06 PL PL10712681T patent/PL2417158T3/pl unknown
- 2010-04-06 WO PCT/US2010/030039 patent/WO2010117980A1/en not_active Ceased
- 2010-04-06 HU HUE19156509A patent/HUE055376T2/hu unknown
- 2010-04-06 LT LTEP10712681.5T patent/LT2417158T/lt unknown
- 2010-04-06 HU HUE10712681A patent/HUE034625T2/en unknown
- 2010-04-06 PT PT107126815T patent/PT2417158T/pt unknown
- 2010-04-06 HU HUE15159780A patent/HUE043904T2/hu unknown
- 2010-04-06 UA UAA201111272A patent/UA103916C2/ru unknown
- 2010-04-06 PT PT191565092T patent/PT3514173T/pt unknown
- 2010-04-06 KR KR1020147005305A patent/KR101461362B1/ko active Active
- 2010-04-06 LT LTEP19156509.2T patent/LT3514173T/lt unknown
- 2010-04-06 EP EP19156509.2A patent/EP3514173B8/en active Active
- 2010-04-06 RS RS20190470A patent/RS58612B1/sr unknown
- 2010-04-06 ES ES15159780T patent/ES2728911T3/es active Active
- 2010-04-06 CA CA2758252A patent/CA2758252C/en active Active
- 2010-04-06 PL PL19156509T patent/PL3514173T3/pl unknown
- 2010-04-06 SG SG2011075579A patent/SG175244A1/en unknown
- 2010-04-06 CN CN201080015994.4A patent/CN102388065B/zh active Active
- 2010-04-06 RS RS20210998A patent/RS62214B1/sr unknown
- 2010-04-06 TR TR2019/07261T patent/TR201907261T4/tr unknown
- 2010-04-06 ME MEP-2019-98A patent/ME03378B/me unknown
- 2010-04-06 KR KR1020147018130A patent/KR20140090273A/ko not_active Ceased
- 2010-04-06 RS RS20170959A patent/RS56505B1/sr unknown
- 2010-04-06 EP EP15159780.4A patent/EP2930184B1/en active Active
- 2010-04-06 ES ES10712681.5T patent/ES2644244T3/es active Active
- 2010-04-06 DK DK19156509.2T patent/DK3514173T3/da active
2011
- 2011-08-25 IL IL214845A patent/IL214845A/en active IP Right Grant
- 2011-10-04 ZA ZA2011/07256A patent/ZA201107256B/en unknown
2017
- 2017-09-29 CY CY20171101022T patent/CY1119399T1/el unknown
2019
- 2019-04-03 HR HRP20190643TT patent/HRP20190643T1/hr unknown
- 2019-05-17 CY CY20191100531T patent/CY1121637T1/el unknown
2021
- 2021-08-06 CY CY20211100700T patent/CY1124412T1/el unknown
- 2021-08-20 HR HRP20211343TT patent/HRP20211343T1/hr unknown

Also Published As

Publication number	Publication date
SG175244A1 (en)	2011-12-29
EP3514173B8 (en)	2021-08-04
CY1119399T1 (el)	2018-02-14
CA2758252C (en)	2015-02-24
KR20140090273A (ko)	2014-07-16
HUE043904T2 (hu)	2019-09-30
PT2930184T (pt)	2019-06-17
RS62214B1 (sr)	2021-09-30
RS56505B1 (sr)	2018-02-28
CY1121637T1 (el)	2020-07-31
TR201907261T4 (tr)	2019-06-21
HUE034625T2 (en)	2018-02-28
EP2417158B9 (en)	2017-12-06
HUE055376T2 (hu)	2021-11-29
JP5759977B2 (ja)	2015-08-05
DK2930184T3 (da)	2019-05-13
ME03378B (me)	2020-01-20
KR20110124364A (ko)	2011-11-16
SI2930184T1 (sl)	2019-06-28
WO2010117980A1 (en)	2010-10-14
UA103916C2 (xx)	2013-12-10
LT3514173T (lt)	2021-09-10
HRP20190643T1 (hr)	2019-05-31
KR20140033523A (ko)	2014-03-18
LT2930184T (lt)	2019-05-10
KR101461362B1 (ko)	2014-11-13
CN102388065B (zh)	2014-09-03
CA2758252A1 (en)	2010-10-14
PT2417158T (pt)	2017-10-23
ES2644244T3 (es)	2017-11-28
EA201171237A1 (ru)	2012-04-30
HRP20171400T1 (hr)	2017-11-03
SI2417158T1 (sl)	2017-10-30
DK2417158T3 (en)	2017-10-16
BRPI1014157A2 (pt)	2020-09-29
TWI546079B (zh)	2016-08-21
EP3514173B1 (en)	2021-06-23
AU2010234611B2 (en)	2013-02-07
US8148498B2 (en)	2012-04-03
EP3514173A1 (en)	2019-07-24
RS58612B1 (sr)	2019-05-31
US20100260754A1 (en)	2010-10-14
DK3514173T3 (da)	2021-08-02
ZA201107256B (en)	2013-03-27
AU2010234611A1 (en)	2011-10-20
IL214845A (en)	2016-06-30
EA021401B1 (ru)	2015-06-30
ES2887176T3 (es)	2021-12-22
EP2417158A1 (en)	2012-02-15
CN102388065A (zh)	2012-03-21
ME02798B (me)	2018-01-20
EP2417158B1 (en)	2017-08-02
IL214845A0 (en)	2011-11-30
ES2728911T3 (es)	2019-10-29
HRP20211343T1 (hr)	2021-11-26
CY1124412T1 (el)	2022-07-22
MX2011010707A (es)	2012-02-28
PT3514173T (pt)	2021-08-16
PL2930184T3 (pl)	2019-10-31
DK2417158T4 (da)	2018-01-29
JP2012523417A (ja)	2012-10-04
NZ595011A (en)	2013-05-31
PL3514173T3 (pl)	2022-01-17
AR075989A1 (es)	2011-05-11
LT2417158T (lt)	2017-10-10
SI3514173T1 (sl)	2021-09-30
TW201100101A (en)	2011-01-01
EP2930184B1 (en)	2019-03-27
EP2930184A1 (en)	2015-10-14
BRPI1014157B1 (pt)	2022-01-18

Publication	Publication Date	Title
DK2930184T3 (da)	2019-05-13	Dkk-1-antistoffer
PT2406284T (pt)	2016-09-29	Anticorpos anti-bcma
DK2462134T3 (da)	2014-08-11	N1-sulfonyl-5-fluorpyrimidinonderivater
EP2473531A4 (en)	2013-05-01	Anti-gitr antibodies
BRPI1011005A2 (pt)	2018-03-06	anticorpos anti-epcam
DK2414015T3 (da)	2021-12-06	Laryngoskopsystem
EP2440486A4 (en)	2013-09-25	CABLE RETRACTION SYSTEM
FI20096144A0 (fi)	2009-11-05	Ulkovalaisu
BRPI1008827A2 (pt)	2016-02-23	deisobutenizador
BRPI1014968A2 (pt)	2016-12-13	subalargador
DE112009005462T8 (de)	2013-03-28	Lenkungsssteuervorrichtung
FI20095891A0 (fi)	2009-08-28	Polttomoottorisovitelma
BRPI1010159A2 (pt)	2016-03-29	bistuti
FI20095852A0 (fi)	2009-08-18	Suuntaajalaite
FI20095735A0 (fi)	2009-06-29	Puhdistinrakenne
DE112010003843T8 (de)	2012-11-29	Lastansteuervorrichtung
FI8691U1 (fi)	2010-04-13	Aukirullain
DK2517018T3 (da)	2015-02-16	Biomarkører
FI20096331A0 (fi)	2009-12-15	Antibodin käyttö
TH0901003923A (th)	2016-02-15	แอนติบอดีหลายความจำเพาะ
TH0901003733A (th)	2015-02-20	องค์ประกอบเชิงภูมิคุ้มกัน
ES1070614Y (es)	2010-01-11	Maleta - botiquin
FI8729U1 (fi)	2010-05-25	Jyrsinturvekääntäjä
FI8495U1 (fi)	2009-10-28	Savupiippuvaraaja
ES1070619Y (es)	2010-01-11	Tenazas corcheras